A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged at least 18 Years

Trial Profile

A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccination Regimen in Adults Aged at least 18 Years

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Dec 2013 According to the ClinicalTrials.gov record, Protocol was amended to add two more treatment arms (increasing from 8 to 10).
    • 30 Oct 2009 Results presented at the 47th Annual Meeting of the Infectious Diseases Society of America.
    • 19 Aug 2009 Actual number of patients changed from 4440 to 4561 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top